Insync Funds Management and Katana Asset Management have jointly announced today the senior appointment of Mr Damen Purcell to lead the distribution of their...

A stellar 12.39% AFTER fees and protection over rolling 5 year periods. Year end April 30th More market volatility in April and continued strong results for...

Insync Fund Managers’ Global Titans Fund has been awarded ‘Favourable’ Approved Investment Grade by SQM Research. The Insync Global Titans Fund aims to del...

19.77% (1 year to October 31st) after the cost of its unique downside protection (not found in other international fund offerings). This return is directly c...

Reckitt Benckiser (RB) is a beneficiary of 2 powerful global megatrends; the rapidly growing middle class in developing countries and the increasing demand f...

Recency Bias Recency bias is our tendency to expect whatever we have recently encountered to persist in the future. When things are going well, we tend to e...

LSE is one of the oldest stock exchanges founded in 1801. Whilst stock exchanges were highly profitable monopolies in the past their original core business h...

Insync Funds Management is pleased to announce the appointment of John Lobb as portfolio manager within the investment team. John has over 25 years of analyt...

Comcast Corp is a global stock benefiting from demand for high speed data Number of internet users around the world now tops 3.4 billion, according to Intern...

"The majority of drinkers of legal age within the next decade will be African." Last month International equities fund manager, Insync Fund Managers, initiat...

Another IMF downgrade would make this year’s growth rate the slowest since the 2009 financial crisis cast the world into recession. Example: Earnings for Med...

"Cloud growth rate is six times higher than world GDP." Microsoft has quickly emerged as a most important cloud computing firm. In a low-growth environment i...

International fund manager sees increasing risk of further market falls in US and Europe Insync has 60% protection over international share portfolio. Active...

"Global pharmaceutical companies benefit from ageing demographics By 2005, 10 percent of global population was aged over 60." While Australians can invest in...

"Bio tech ‘fits’ well into portfolios seeking growth in a low-growth world markets for life science tools/diagnostics is nearly $US100 billion per annum." In...